Mersana Therapeutics, Inc. Proceeds from Common Stock Issued
Mersana Therapeutics, Inc. reported Proceeds from Common Stock Issued of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-11-14
- Mersana Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $0.00.
- Mersana Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2025-06-30 was $0.00.
- Mersana Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Mersana Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $0.00.
- Mersana Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2019 was $92.16M.
| Period end | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$66.00K derived: sum of 2 quarters · filed 2025-11-14 | $5.78M 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | -$66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $5.78M 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $5.85M 10-Q · filed 2025-05-15 | ||||
| 2023-09-30 | -$81.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $71.81M derived: sum of 2 quarters · filed 2024-11-13 | $93.54M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $71.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $93.62M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $21.73M 10-Q · filed 2024-05-09 | ||||
| 2022-09-30 | $10.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $50.58M derived: sum of 2 quarters · filed 2023-11-07 | $110.95M 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $39.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $100.36M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $60.37M 10-Q · filed 2023-05-09 | ||||
| 2021-09-30 | -$51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $33.29M 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | $33.34M 10-Q · filed 2022-08-08 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $0.00 derived: sum of 2 quarters · filed 2020-02-28 | $0.00 derived: sum of 3 quarters · filed 2020-02-28 | $92.16M 10-K · filed 2020-02-28 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $92.16M 10-Q · filed 2019-11-06 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $92.16M 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $92.16M 10-Q · filed 2019-11-06 | $92.16M 10-Q · filed 2020-05-08 |